Vaxxas, a clinical-stage biotechnology company commercializing a novel vaccination platform, today announced the publication of data supporting the effective use of its high-density microarray patch ...
Recombinant DNA technology allowed ... invasive disease in one region of the world. Thus, a vaccine might offer good coverage in, for example, the United States, but offer poorer coverage in ...
Integrating best practices in AI, genomics, cell culture, and laboratory techniques together contribute to protein expression success.
A variety of vaccine approaches, however, have been investigated using both inactivated virus and recombinant DNA technology. These approaches will be further discussed later in this review.
LMU researchers have shown that a particular type of immune cell acts more flexibly than previously thought—with the ...
Visit us on Facebook. Opens in a new tab or window Visit us on X. Opens in a new tab or window Visit us on Instagram. Opens in a new tab or window Visit us on LinkedIn. Opens in a new tab or ...
bViral Epidemiology and Immunity Unit, Laboratory of Infectious Diseases, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA cSealy Institute for ...
Feb. 26, 2025 — Pre-existing immunity against seasonal H1N1 flu might help explain why most reported human cases of H5N1 bird flu in the U.S. have not resulted in lethal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback